

November 12, 2020

To,
Department of Corporate Service
BSE Limited,

Registered Office : Floor 25, P. J. Towers,
Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.
T: 2272 1233 / 1234 | F : 2272 3121 / 3719 | www.bseindia.com

Subject : Approval of Standalone Un-Audited Financial Results for the quarter
and half year ended September 30, 2020.

Reference : Centenial Surgical Suture Ltd. | Scrip Code: 531380

Dear Sir,

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit following documents:

- 1). Standalone Un-Audited Financial Results for the quarter and half year ended September 30, 2020.
- 2). Statement of Assets and Liabilities for the half year ended September 30, 2020.
- 3). Statement of Cash Flow for the half year ended September 30, 2020.
- 4). Limited Review Report for the quarter and half year ended September 30, 2020.

You are requested to kindly take the same on your record.

Sincerely,

For **CENTENIAL SURGICAL SUTURE LTD.**



Mahima BATHWAL
Company Secretary & Compliance Officer

Enclosures : as mentioned above.

- Registered Office**
F-29, MIDC, Murbad, Thane 421401
MAHARASHTRA.
☎ 912524222905 Fax 912524222905
- Manufacturing Facility**
B-17 / F-29 / F-22 MIDC, Murbad,
Thane 421401. MAHARASHTRA.
☎ 2524223200 Fax 912524 222872
- Sales Office - Mumbai**
1st Floor, Palai Complex CHS Ltd.,
Bhandarkar Road, Matunga (East),
Mumbai 400019. MAHARASHTRA.
☎ 912224102876 Fax 912224161261
- Sales Office - Bengaluru**
No.12/42, Udhani Layout,
Off. Cambridge Road, Halasur,
Bengaluru 560008. KARNATAKA.
☎ 9180 25577791 Fax 9180 25577792
- Sales Office - Kolkata**
Flat No. N-1, Ground Floor, 385,
Purbachal, Kalitala Road, P.S.Kasba,
Kolkata 700078. WEST BENGAL.
☎ 91 3324844875 Fax 91 3324844875

Statement of Standalone Un-Audited Financial Results for the Quarter ended September 30, 2020

(Rs. In Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income						
	Revenue from Operations	813.66	602.39	1415.23	1416.04	2847.72	5561.43
	Other Income	-	0.47	0.32	0.47	0.56	9.26
	Total Revenue	813.66	602.85	1415.55	1416.51	2848.28	5570.69
II	Expenses :						
	(a) Cost of Materials Consumed	375.79	327.57	637.74	703.36	1218.74	2455.26
	(b) Purchases of Stock-in-Trade	-	-	-	-	28.80	37.02
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	(288.37)	(273.21)	(78.98)	(561.57)	(85.53)	(63.32)
	(d) Employee Benefits Expense	238.87	224.07	234.02	462.93	491.00	1067.37
	(e) Finance Costs	44.98	25.13	28.65	70.11	58.50	218.32
	(f) Depreciation and Amortisation Expense	43.79	38.36	16.65	82.15	32.29	155.39
	(g) Other Expenses	345.85	239.59	503.29	585.45	973.65	1485.15
	Total expenses	760.91	581.51	1341.37	1342.42	2717.45	5355.19
III	Profit / (Loss) before Exceptional items and Tax (I - II)	52.74	21.34	74.18	74.09	130.83	215.50
IV	Exceptional Items	-	-	-	-	-	-
V	Profit / (Loss) after Exceptional items and Tax (III-IV)	52.74	21.34	74.18	74.09	130.83	215.50
VI	Tax Expense :						
	(1) Current Tax	13.71	5.55	16.27	19.26	32.03	71.58
	(2) Deferred tax	-	-	-	-	-	14.33
	Total Tax Expenses	13.71	5.55	16.27	19.26	32.03	85.91
VII	Profit / (Loss) for the period from Continuing Operations (V - VI)	39.03	15.79	57.91	54.82	98.80	129.59
VIII	Profit / (Loss) from Discontinuing Operations	-	-	-	-	-	-
IX	Tax expenses of Discontinuing Operations	-	-	-	-	-	-
X	Profit / (Loss) From Discontinuing Operations (after tax) (VIII-IX)	-	-	-	-	-	-
XI	Profit / (Loss) for the period (VII+X)	39.03	15.79	57.91	54.82	98.80	129.59
XII	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII	Total Comprehensive Income for the period	39.03	15.79	57.91	54.82	98.80	129.59
XIV	Details of Equity share capital						
	Paid up Equity capital (Face Value of Rs.10/- each)	364.83	364.83	364.83	364.83	364.83	364.83
	Face value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
XV	Earnings Per Equity Share for Continuing operation :						
	(a) Basic	1.07	0.43	1.59	1.50	2.71	3.55
	(b) Diluted	1.07	0.43	1.59	1.50	2.71	3.55
XVI	Earnings Per equity share for Discontinuing operation :						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XVII	Earnings Per Equity Share for Discontinuing & Continuing operation :						
	(a) Basic	1.07	0.43	1.59	1.50	2.71	3.55
	(b) Diluted	1.07	0.43	1.59	1.50	2.71	3.55



Statement of Assets and Liabilities

Rs. In Lakhs

	Particulars	As at September 30, 2020	As at March 31, 2020
I	ASSETS		
1)	Non-current assets		
	a) Property, Plant and Equipment	980.06	1,043.15
	b) Capital work-in-progress	25.73	22.23
	c) Other Intangible assets	0.81	0.98
	d) Financial assets		-
	(i) Loans		-
	(ii) Other financial assets	26.73	30.90
	e) Deferred tax assets (net)		-
	f) Income-tax assets (net)	10.51	17.78
	g) Other non-current assets		-
	Total Non-current assets (1)	1,043.84	1,115.02
2)	Current assets		
	a) Inventories	3,736.00	3,219.84
	b) Financial assets		
	(i) Trade receivables	1,949.12	2,335.31
	(ii) Cash and cash equivalents	15.29	72.29
	(iii) Bank balances other than (ii) above	-	-
	(iv) Loans	-	-
	(v) Other current financial assets	0.58	0.93
	c) Other current assets	160.24	138.25
	Total Current assets (2)	5,861.23	5,766.62
	TOTAL ASSETS (I = 1 + 2)	6,905.07	6,881.63
II	EQUITY & LIABILITIES		
1)	Equity		
	a) Equity Share capital	542.43	542.43
	b) Other Equity	2,373.31	2,318.49
	Total Equity (1)	2,915.74	2,860.92
2)	Liabilities		
	Non-current liabilities		
	a) Financial Liabilities		
	(i) Other financial liabilities	990.19	957.31
	b) Long-term provisions	(19.56)	(19.56)
	c) Deferred tax liabilities (net)	14.33	14.33
	Total Non-current liabilities	984.97	952.09
	Current liabilities		
	a) Financial Liabilities		
	(i) Trade payables	877.53	1,251.234
	(ii) Other current financial liabilities	2,125.84	1,821.58
	b) Other current liabilities	0.99	(4.20)
	c) Short-term provisions		-
	Total Current liabilities	3,004.36	3,068.62
	Total Liabilities (2)	3,989.33	4,020.70
	TOTAL EQUITY AND LIABILITIES (II = 1 + 2)	6,905.07	6,881.63



Cash Flow Statement for the Quarter and Half Year ended September 30, 2020

Rs. In Lakhs

Particulars	As at September 30, 2020	As at March 31, 2020
A. Cash flow from operating activities		
Net Profit before tax	74.09	215.50
Adjustments for :		
Depreciation and amortisation expense	82.15	155.39
Interest income	(0.47)	(1.67)
Reclassification on account of adoption of Ind AS 116	-	(39.57)
Profit on redemption of mutual funds (net)	-	-
Exchange gain	(0.86)	6.63
Provision for Leave encashment	-	-
Provision for Gratuity	-	19.56
Sundry balances written back/written-off		-
Operating profit before working capital changes	154.91	355.84
Adjustments for :		
Decrease / (Increase) in inventories	(516.16)	(237.71)
Decrease / (Increase) in trade receivable	386.18	(264.83)
Decrease / (Increase) in financials and non-financial assets	11.77	(21.74)
Decrease / (Increase) in other assets and receivables	(21.99)	(5.86)
(Decrease) / Increase in trade and other payables	9.77	468.07
Cash generated from operations	24.48	293.77
Income tax refund / (paid)	(19.26)	(85.91)
Net cash (used in) / generated from operating activities	5.22	207.86
B. Cash flow from investing activities		
Acquisition of fixed assets and capital work in progress	(22.39)	(107.93)
Proceeds from sale of investments	-	1.64
Interest income on fixed deposits and other advances	1.33	(24.53)
Net cash (used in) / generated from investing activities	(21.06)	(130.81)
C. Cash flow from financing activities		
Proceeds from issuance of Debentures		-
Proceeds from Short term borrowings	(41.16)	(37.38)
Net cash (used in) / generated from financing activities	(41.16)	(37.38)
Net (decrease) / increase in cash and cash equivalents (A+B+C)	(57.00)	39.66
Cash and cash equivalents as at the beginning of year	72.29	32.62
Cash and cash equivalents at the end of year	15.29	72.29
Components of cash and cash equivalents (Also, refer note 10)		
Cash in hand	1.70	2.27
Balance with scheduled banks in current accounts	13.59	70.02
Total	15.29	72.29



Notes:

- 1). The above Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2020 ("Statement") is prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on November 12, 2020. The Statement is subjected to 'limited review' by the Auditors of the Company and their report contains no qualification.
- 2). The Company has one reportable business segment "Medical Devices".
- 3). In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a Limited Review of the Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2020.
- 4). The industry as a whole has been adversely impacted by the spread of COVID-19. The Company faces significant headwinds due to COVID-19 which have impacted the operations of the Company adversely starting from the month of March 2020 onwards particularly by way of closures due to complete lockdown. This unprecedented disruption has had an adverse impact on the quarterly performance and continue to impact the business and our financial results. In this crisis, our priorities are to protect our employees and their families from COVID-19 and the society associated with it. We do anticipate material risk to business prospects over the medium to long term. The Company has begun restoration of operations as permitted by the Government and Local / Regulatory authorities, with controlled movement, maintaining social distancing, taking appropriate hygiene measures and following the directions of regulatory authorities. The Company has evaluated impact on its business operations and financial position based on its review of current indicators of future economic conditions. The Company is closely monitoring the developments and possible effects that may result from the current pandemic on its financial condition, liquidity and operations and is actively working to minimize the impact of this unprecedented situation. As the situation is continuously evolving, the eventual impact may be different from the estimates made as of the date of approval of these Results.
- 5). The Code on Social Security 2000 (the 'Code') relating to employee benefits during employment and post-employment benefits was approved by the Parliament and received Presidential Assent in September 2020. The Code has also been published in the Gazette of India. However, the effective date and the rules pertaining to the code are yet to be notified/framed. The Company will assess the impact of the Code when it is made effective and will record the related financial impact, if any, in the period in which the Code becomes effective.
- 6). The Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2020 are available on the website of BSE Limited at www.bseindia.com and on Company's website at www.centenialindia.com.

Place : Mumbai, Maharashtra
 Date : November 12, 2020



for CENTENIAL SURGICAL SUTURE LTD.

Vijay MAJREKAR
 Managing Director & Chief Executive Officer
 DIN : 00804808

Mahesh Chandra & Associates
Chartered Accountants

**Independent Auditor's Review Report on the Quarter and Half Year ended September 30, 2020
Standalone Un-Audited Financial Results of the Company Pursuant to the Regulation 33 of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To,
The Board of Directors
CENTENIAL SURGICAL SUTURE LTD.
Registered Office : F-29, M.I.D.C., Murbad,
Thane 421401. MAHARASHTRA.

We have reviewed the accompanying Statement of Standalone Un-Audited Financial Results of Centenial Surgical Suture Limited ("the Company") for the quarter and half year ended September 30, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended ("the Regulation") read with SEBI Circular No: CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").

This "statement" which is the responsibility of the Company's Management and approved by the Board of Directors at their meeting held on November 12, 2020 has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Mahesh Chandra & Associates
Chartered Accountants,
Firm Registration No.: 112334W



RAJESH BOHRA

Partner ~ Membership No.102587
UDIN: 20102587AAAKCR2926

Date : November 12, 2020
Place : Mumbai, MAHARASHTRA.